Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 944 - 951 |
| Number of pages | 8 |
| Journal | Journal of Neurology, Neurosurgery and Psychiatry |
| Volume | 87 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Arts and Humanities (miscellaneous)
- Clinical Neurology
- Psychiatry and Mental health
Cite this
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. / Patti, F.; Messina, S.; Solaro, C.; Amato, M.P.; Bergamaschi, R.; Bonavita, S.; Bruno Bossio, R.; Brescia Morra, V.; Costantino, G.F.; Cavalla, P.; Centonze, D.; Comi, Giancarlo; Cottone, S.; Danni, M.; Francia, A.; Gajofatto, A.; Gasperini, C.; Ghezzi, A.; Iudice, A.; Lus, G.; Maniscalco, G.T.; Marrosu, M.G.; Matta, M.; Mirabella, M.; Montanari, E.; Pozzilli, C.; Rovaris, M.; Sessa, E.; Spitaleri, D.; Trojano, M.; Valentino, P.; Zappia, M.
In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, No. 9, 01.09.2016, p. 944 - 951.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
AU - Patti, F.
AU - Messina, S.
AU - Solaro, C.
AU - Amato, M.P.
AU - Bergamaschi, R.
AU - Bonavita, S.
AU - Bruno Bossio, R.
AU - Brescia Morra, V.
AU - Costantino, G.F.
AU - Cavalla, P.
AU - Centonze, D.
AU - Comi, Giancarlo
AU - Cottone, S.
AU - Danni, M.
AU - Francia, A.
AU - Gajofatto, A.
AU - Gasperini, C.
AU - Ghezzi, A.
AU - Iudice, A.
AU - Lus, G.
AU - Maniscalco, G.T.
AU - Marrosu, M.G.
AU - Matta, M.
AU - Mirabella, M.
AU - Montanari, E.
AU - Pozzilli, C.
AU - Rovaris, M.
AU - Sessa, E.
AU - Spitaleri, D.
AU - Trojano, M.
AU - Valentino, P.
AU - Zappia, M.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background The approval of 9-δ-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex) for the management of treatment-resistant multiple sclerosis (MS) spasticity opened a new opportunity for many patients. The aim of our study was to describe Sativex effectiveness and adverse events profile in a large population of Italian patients with MS in the daily practice setting. Methods We collected data of all patients starting Sativex between January 2014 and February 2015 from the mandatory Italian medicines agency (AIFA) e-registry. Spasticity assessment by the 0-10 numerical rating scale (NRS) scale is available at baseline, after 1month of treatment (trial period), and at 3 and 6months. Results A total of 1615 patients were recruited from 30 MS centres across Italy. After one treatment month (trial period), we found 70.5% of patients reaching a ≥20% improvement (initial response, IR) and 28.2% who had already reached a ≥30% improvement (clinically relevant response, CRR), with a mean NRS score reduction of 22.6% (from 7.5 to 5.8). After a multivariate analysis, we found an increased probability to reach IR at the first month among patients with primary and secondary progressive MS, (n=1169, OR 1.4 95% CI 1.04 to 1.9, p=0.025) and among patients with >8 NRS score at baseline (OR 1.8 95% CI 1.3-2.4 p
AB - Background The approval of 9-δ-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex) for the management of treatment-resistant multiple sclerosis (MS) spasticity opened a new opportunity for many patients. The aim of our study was to describe Sativex effectiveness and adverse events profile in a large population of Italian patients with MS in the daily practice setting. Methods We collected data of all patients starting Sativex between January 2014 and February 2015 from the mandatory Italian medicines agency (AIFA) e-registry. Spasticity assessment by the 0-10 numerical rating scale (NRS) scale is available at baseline, after 1month of treatment (trial period), and at 3 and 6months. Results A total of 1615 patients were recruited from 30 MS centres across Italy. After one treatment month (trial period), we found 70.5% of patients reaching a ≥20% improvement (initial response, IR) and 28.2% who had already reached a ≥30% improvement (clinically relevant response, CRR), with a mean NRS score reduction of 22.6% (from 7.5 to 5.8). After a multivariate analysis, we found an increased probability to reach IR at the first month among patients with primary and secondary progressive MS, (n=1169, OR 1.4 95% CI 1.04 to 1.9, p=0.025) and among patients with >8 NRS score at baseline (OR 1.8 95% CI 1.3-2.4 p
UR - http://www.scopus.com/inward/record.url?scp=84969138568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969138568&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2015-312591
DO - 10.1136/jnnp-2015-312591
M3 - Article
VL - 87
SP - 944
EP - 951
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
SN - 0022-3050
IS - 9
ER -